Elagolix + Placebo for Estradiol/Norethindrone Acetate + Estradiol/Norethindrone Acetate + Placebo for Elagolix

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Uterine Fibroids

Conditions

Uterine Fibroids, Heavy Menstrual Bleeding

Trial Timeline

Feb 3, 2016 → Jan 23, 2019

NCT ID

NCT02691494

About Elagolix + Placebo for Estradiol/Norethindrone Acetate + Estradiol/Norethindrone Acetate + Placebo for Elagolix

Elagolix + Placebo for Estradiol/Norethindrone Acetate + Estradiol/Norethindrone Acetate + Placebo for Elagolix is a phase 3 stage product being developed by AbbVie for Uterine Fibroids. The current trial status is completed. This product is registered under clinical trial identifier NCT02691494. Target conditions include Uterine Fibroids, Heavy Menstrual Bleeding.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02691494	Phase 3	Completed	Feb 3, 2016	Jan 23, 2019	Uterine Fibroids
NCT02654054	Phase 3	Completed	Dec 22, 2015	Dec 12, 2018	Uterine Fibroids

Competing Products

20 competing products in Uterine Fibroids

See all competitors

Product	Company	Stage	Hype Score
Azenosertib	Zentalis Pharmaceuticals	Phase 2	44
Amolimogene + Amolimogene	Eisai	Phase 2/3	65
Relugolix Combination Tablet	Sumitomo Pharma	Phase 3	77
SHR7280 tablets + SHR7280 tablets + PlaceboSHR7280 tablets blank preparation	Jiangsu Hengrui Medicine	Phase 2/3	65
SHR7280 tablets + SHR7280 dry suspension	Jiangsu Hengrui Medicine	Phase 1	33
Elagolix + 0.5 mg estradiol / 0.1 mg norethindrone acetate + 1 mg estradiol / 0.5 mg norethindrone acetate + E2/NETA placebo	AbbVie	Phase 2	52
Estradiol/Norethindrone Acetate + Elagolix	AbbVie	Phase 3	77
Elagolix + Placebo	AbbVie	Approved	85
Elagolix + Placebo + Estradiol/Norethindrone acetate (E2/NETA) + Estradiol + Progesterone	AbbVie	Phase 2	52
Elagolix + Placebo for Estradiol/Norethindrone Acetate + Estradiol/Norethindrone Acetate + Placebo for Elagolix	AbbVie	Phase 3	77
Adavosertib	AstraZeneca	Phase 2	52
AZD1775	AstraZeneca	Phase 2	52
Saizen® A + Saizen® B	Merck	Phase 3	77
Bintrafusp alfa	Merck	Phase 2	52
Pembrolizumab + Lenvatinib	Merck	Phase 2	52
Pembrolizumab + Placebo for pembrolizumab + Cisplatin	Merck	Phase 3	77
Pembrolizumab (Keytruda)	Merck	Phase 1	33
Pembrolizumab/Vibostolimab Co-Formulation + Pembrolizumab + Lenvatinib + 5-Fluorouracil + Cisplatin + Paclitaxel + Gemcitabine + Carboplatin + Docetaxel + Bevacizumab + Capecitabine + Oxaliplatin	Merck	Phase 2	52
Zoledronic acid	Novartis	Phase 2	52
KLH-2109 + Leuprorelin	Kissei Pharmaceutical	Phase 3	76

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved

CREONApproved

Venetoclax + AzacitidineApproved

Oxybutynin + PlaceboApproved

Glecaprevir-pibrentasvirApproved